NFKB1 and cancer: The reduced intratumoral immune cell infiltration due to IL30-targeting treatment was accompanied by substantial inhibition in cancer cells expression of NFKB1 (Fig. 8n), which is a key player in cancer-immune cell crosstalk and in modulating antitumor immunity28.